Lucid Diagnostics (ticker: LUCD) reported processing 3,034 EsoGuard tests in the first quarter, generating $0.8 million in revenue and holding $40 million in proforma cash. The company is awaiting a Medicare local coverage decision, expected imminently this quarter, which could shift its business from volume growth to revenue growth. EsoGuard is currently the only FDA-approved test for screening Barrett's Esophagus and esophageal adenocarcinoma. Analysts from Cantor have assigned an overweight rating to LUCD, highlighting the potential impact of Medicare coverage on the company's fundamentals and long-term valuation, with price targets ranging from $5 to over $10 per share. Separately, the Liquidium token, associated with the Bitcoin ecosystem, is considered undervalued by market observers, citing its existing revenue, business pipeline, and upcoming revenue sharing for stakers. The token's market capitalization is projected to reach $250 million or more, with a long-term target exceeding $1 billion.